ArticleEuropean urology open science2026
Identifying Candidates for Biopsy Omission in Prostate Cancer Using mpMRI and PSMA PET/CT.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The superior diagnostic capabilities of novel imaging modalities such as multiparametric prostate magnetic resonance imaging MRI (mpMRI) and prostate-specific membrane-antigen positron emission tomography/computed tomography (PSMA PET/CT) might provide data for consideration of a prostate biopsy-omitting approach in a selected subgroup of patients with prostate cancer. Methods: Patients who underwent radical prostatectomy (RP) for prostate cancer between December 2015 and December 2024 were retrospectively evaluated, and only patients who underwent mpMRI and PSMA PET/CT were included in the study. After recording patient characteristics (age, prostate-specific antigen [PSA], PSA density [PSAD]), mpMRI characteristics (Prostate Imaging Reporting And Data System [PI-RADS] score, number of lesions, size of the index lesion), and PSMA PET characteristics (prostatic SUVmax ≥12 = PRIMARY 5), adverse pathology (≥pT3a or pN1 or GG≥3) rates at RP were investigated. Multivariable logistic regression analysis was performed to determine the independent predictors of adverse pathology. Results: The median age and serum PSA of 413 patients included in the study were 64.9 years (interquartile range [IQR]: 58.3-69.9) and 7.0 ng/dl (IQR: 4.9-9.4). The RP pathology revealed that 248 out of 413 patients (60%) had adverse features (58 out of 413 had GG4 or 5 disease). The multivariable analysis revealed that age, serum PSAD, PI-RADS-5 score on mpMRI, and prostatic SUVmax ≥12 (PRIMARY-5) on PSMA PET were independent predictors of adverse pathology. Based on these results, the combination of PSAD, MRI, and PSMA PET has consistently resulted in adverse pathology: PSAD >0.15 ng/ml/cc AND PI-RADS-5 AND PRIMARY 5. Conclusions: A combination of serum PSAD, PI-RADS score on mpMRI, and PRIMARY score on PSMA PET/CT has consistently resulted in adverse pathology, indicating consideration of a biopsy-omitting approach if further studies endorse these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.